The DOI matches its Crossref record; 300 of the 300 references it cites were found in a registry or an index.
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Open accessAbstract
Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–300 of 300
Cancer Nanomedicine: A New Era of Successful Targeted Therapy
El-Readi, M. Z., & Althubiti, M. (2019) · Journal of Nanomaterials · doi:10.1155/2019/4927312 · Cited by 103
Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer
Reck, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0121 · Cited by 101
Cyprian, F. S., Akhtar, S., Gatalica, Z., & Vranić, S. (2019) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2019.4204 · Cited by 101
Therapeutic Potential of Nitrogen Mustard Based Hybrid Molecules
Chen, Y., Jia, Y., Song, W., & Zhang, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01453 · Cited by 97
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-1022-3 · Cited by 96
Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy
Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 96
Epigenetic Control of the Tumor Microenvironment
Marks, D. L., Olson, R. L., & Fernández-Zapico, M. E. (2016) · Epigenomics · doi:10.2217/epi-2016-0110 · Cited by 95
Atezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94
Irinotecan-induced mucositis is associated with changes in intestinal mucins
Stringer, A. M., Gibson, R. J., Logan, R. M., Bowen, J. M., Yeoh, A. S. J., Laurence, J., & Keefe, D. M. K. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0855-y · Cited by 94
Decitabine in the treatment of acute myeloid leukemia in elderly patients
Cashen, A. F., & Malik, P. (2014) · Cancer Management and Research · doi:10.2147/cmar.s40600 · Cited by 92
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Sun, G., Rong, D., Li, Z., Sun, G., Wu, F., Li, X., Cao, H., Cheng, Y., Tang, W., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694363 · Cited by 91
Wu, W. K. K., Wu, Y. C., Yu, L., Li, Z. J., Sung, J. J. �., & Cho, C. H. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.031 · Cited by 89
Barone, A. K., Chi, D.-C., Theoret, M. R., Chen, H., He, K., Kufrin, D., Helms, W. S., Subramaniam, S., Zhao, H., Patel, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0898 · Cited by 89
Clinical Next Generation Sequencing for Precision Medicine in Cancer
Dong, L., Wang, W., Li, A., Kansal, R., Chen, Y., Chen, H., & Li, X. (2015) · Current Genomics · doi:10.2174/1389202915666150511205313 · Cited by 88
Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis?
Whiteside, T. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00107 · Cited by 87
Safety and Tolerability of Adoptive Cell Therapy in Cancer
Wolf, B., Zimmermann, S., Arber, C., Irving, M. B., Trueb, L., & Coukos, G. (2019) · Drug Safety · doi:10.1007/s40264-018-0779-3 · Cited by 87
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Laplagne, C., Domagala, M., Naour, A. L., Quémerais, C., Hamel, D., Fournié, J., Couderc, B. C., Bousquet, C., Ferrand, A., & Poupot, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194719 · Cited by 87
Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Yu, F., Zhu, C., Xie, Q., & Wang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00237 · Cited by 86
Guidelines for treatment of renal injury during cancer chemotherapy 2016
Horie, S., Oya, M., Nangaku, M., Yasuda, Y., Komatsu, Y., Yanagita, M., Kitagawa, Y., Kuwano, H., Nishiyama, H., Ishioka, C., et al. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1448-z · Cited by 84
The evolving role of DNA inter-strand crosslinks in chemotherapy
Rycenga, H. B., & Long, D. T. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.004 · Cited by 83
Niemirowicz, K., Prokop, I., Wilczewska, A. Z., Wnorowska, U., Piktel, E., Wątek, M., Savage, P. B., & Bucki, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s76104 · Cited by 82
Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment
Pan, X., & Zheng, L. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0505-9 · Cited by 82
Dioscin: A review on pharmacological properties and therapeutic values
Bandopadhyay, S., Anand, U., Gadekar, V. S., Jha, N. K., Gupta, P. K., Behl, T., Kumar, M., CHAUHAN, R., Shekhawat, M. S., & Dey, A. (2021) · BioFactors · doi:10.1002/biof.1815 · Cited by 82
Self-citationArndt, C., Hawkins, D. S., Anderson, J. R., Breitfeld, P. P., Womer, R. B., & Meyer, W. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.075 · Cited by 79
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Lee, C., Huang, Y.-W., Yang, C.-H., & Huang, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150414120547 · Cited by 77
Mitchell, T., & Turton, P. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01244.x · Cited by 72
Cancer: We Should Not Forget The Past
Lonardo, A. D., Nasi, S., & Pulciani, S. (2014) · Journal of Cancer · doi:10.7150/jca.10336 · Cited by 71
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
Dewanjee, S., Vallamkondu, J., Kalra, R. S., Chakraborty, P., Gangopadhyay, M., Sahu, R., Medala, V. K., John, A. A., Reddy, P. H., Feo, V. D., et al. (2021) · Cells · doi:10.3390/cells10061340 · Cited by 71
Self-citationTargeting adenosine and regulatory T cells in cancer immunotherapy
Churov, A. V., & Жулай, Г. А. (2021) · Human Immunology · doi:10.1016/j.humimm.2020.12.005 · Cited by 70
Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic
Finn, O. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0110 · Cited by 69
Kang, C., & Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01295-y · Cited by 68
Jiang, G., Li, R.-H., Sun, C., Liu, Y., & Zheng, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111920 · Cited by 67
Combating Drug-Resistant Bacteria Using Photothermally Active Nanomaterials: A Perspective Review
Kaur, K., Reddy, S. M. L., Barathe, P., Shriram, V., Anand, U., Proćków, J., & Kumar, V. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.747019 · Cited by 67
Self-citationTargeted Delivery of Bleomycin: A Comprehensive Anticancer Review
Yu, Z., Yan, B., Gao, L., Dong, C., Zhong, J. Q., D'Ortenzio, M., Nguyen, B. T., Lee, S. S., Hu, X., & Feng, L. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151130213910 · Cited by 64
A review of arsenic trioxide and acute promyelocytic leukemia.
Alimoghaddam, K. (2014) · Europe PMC (PubMed Central) · Cited by 62
Kroemer, G., & Zitvogel, L. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201979 · Cited by 62
Stewart, D. A., Winnike, J. H., McRitchie, S., Clark, R. F., Pathmasiri, W., & Sumner, S. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00430 · Cited by 61
Tumor Microenvironment: No Effector T Cells without Dendritic Cells
Pfirschke, C., Siwicki, M. R., Liao, H.-W., & Pittet, M. J. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.007 · Cited by 60
The war on cancer: are we winning?
Duffy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0759-2 · Cited by 59
Lu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q., Sun, S., Guo, X., Yin, H., Wei, Y., Li, S., et al. (2020) · Hepatology · doi:10.1002/hep.31502 · Cited by 56
Mitra, S., Anand, U., Sanyal, R., Jha, N. K., Behl, T., Mundhra, A., Ghosh, A., Radha, Kumar, M., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112378 · Cited by 55
Self-citationMetastatic melanoma – a review of current and future drugs
Velho, T. R. (2012) · Drugs in Context · doi:10.7573/dic.212242 · Cited by 54
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
Hasanali, Z. S., Saroya, B. S., Stuart, A., Shimko, S., Evans, J. J., Shah, M. V., Sharma, K., Leshchenko, V. V., Parekh, S. S., Loughran, T. P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5079 · Cited by 53
Leung, J. C., & Cassimeris, L. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1638678 · Cited by 52
Exploring DNA-Binding Proteins with In Vivo Chemical Cross-Linking and Mass Spectrometry
Qiu, H., & Wang, Y. (2009) · Journal of Proteome Research · doi:10.1021/pr8009319 · Cited by 51
Proteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Mishra, R., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21502 · Cited by 51
Self-citationPharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies
Said, R., & Tsimberidou, A. M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.885016 · Cited by 50
Topotecan-Triggered Degradation of Topoisomerase I Is p53-Dependent and Impacts Cell Survival
Tomicic, M. T., Christmann, M., & Kaina, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0266 · Cited by 49
Datta, S., Ramamurthy, P. C., Anand, U., Singh, S., Singh, A., Dhanjal, D. S., Dhaka, V., Kumar, S., Kapoor, D., Nandy, S., et al. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.08.036 · Cited by 49
Self-citationBapat, S. A., Krishnan, A., Ghanate, A. D., Kusumbe, A. P., & Kalra, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0447 · Cited by 48
High content screening identifies monensin as an EMT-selective cytotoxic compound
Vanneste, M., Huang, Q., Li, M., Moose, D. L., Zhao, L. Q., Stamnes, M. A., Schultz, M. K., Wu, M., & Henry, M. D. (2019) · Scientific Reports · doi:10.1038/s41598-018-38019-y · Cited by 47
Franco, R., Rivas‐Santisteban, R., Navarro, G., & Reyes‐Resina, I. (2021) · Cells · doi:10.3390/cells10112831 · Cited by 47
Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Haque, A., Rahman, M. A., Faizi, M. S. H., et al. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170502123639 · Cited by 46
From Antimicrobial to Anticancer Peptides: The Transformation of Peptides
Qin, Y. H., Qin, Z. D., Chen, J., Cai, C. G., Li, L., Feng, L., Wang, Z., Duns, G. J., He, N. Y., Chen, Z., et al. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666190119165157 · Cited by 44
Shoshan‐Barmatz, V., Anand, U., Crystal, E. N., Carlo, M. D., & Shteinfer‐Kuzmine, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.730048 · Cited by 44
Self-citationNew approaches for cancer immunotherapy
Karlıtepe, A., Özalp, Ö., & Avcı, Ç. B. (2015) · Tumor Biology · doi:10.1007/s13277-015-3491-2 · Cited by 43
Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer
Voznesensky, M. A., Annam, K., & Kreder, K. J. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.010678 · Cited by 42
Kalra, R. S., Chaudhary, A., Yoon, A. R., Bhargava, P., Omar, A., Garg, S., Yun, C., Kaul, S. C., & Wadhwa, R. (2018) · Oncogenesis · doi:10.1038/s41389-018-0048-4 · Cited by 42
Self-citationHow autophagy can restore proteostasis defects in multiple diseases?
Joshi, V., Upadhyay, A., Prajapati, V. K., & Mishra, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21662 · Cited by 41
Self-citationInnovative Technologies Changing Cancer Treatment
Charmsaz, S., Prencipe, M., Bailey‐Whyte, M., Pidgeon, G. P., & Collins, D. M. (2018) · Cancers · doi:10.3390/cancers10060208 · Cited by 40
Advancing oncolytic virus therapy by understanding the biology
Kaufman, H. L., & Maciorowski, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00490-4 · Cited by 40
New insight into NANOG: A novel therapeutic target for ovarian cancer (OC)
Iyer, M., Devi, S. M., Jayaramayya, K., Arul, N. S., Vellingiri, B., & Santhy, K. S. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.003 · Cited by 39
Matt, P., van Zwieten‐Boot, B., Calvo, G., ter Hofstede, H. J. M., García‐Carbonero, R., Camarero, J., Abadie, E., & Pignatti, F. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0224 · Cited by 38
Taxanes: their impact on gynecologic malignancy
Schwab, C. L., English, D. P.-G., Roque, D. M., & Santin, A. D. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000057 · Cited by 37
Synthesis of CPT‐11 (Irinotecan Hydrochloride Trihydrate)
SAWADA, S., Yokokura, T., & MIYASAKA, T. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26372.x · Cited by 34
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Kim, I., Sanchez, K. G., McArthur, H. L., & Page, D. B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00345-z · Cited by 34
Yan, W., Ling, L., Wu, Y., Yang, K., Liu, R., Zhang, J., Zhao, S., Zhong, G., Zhao, S., Jiang, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01155 · Cited by 33
Dutta, T., Anand, U., Saha, S. C., Mane, A. B., Prasanth, D. A., Kandimalla, R. J. L., Proćków, J., & Dey, A. (2021) · Conservation Physiology · doi:10.1093/conphys/coab073 · Cited by 32
Self-citationAtezolizumab in the treatment of metastatic triple-negative breast cancer
Pérez-García, J. M., Soberino, J., Racca, F., Gión, M., Stradella, A., & Cortés, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1769063 · Cited by 31
Antimicrobial peptides against colorectal cancer-a focused review
Chauhan, S., Dhawan, D. K., Saini, A., & Preet, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105529 · Cited by 31
Ibuprofen Induces Mitochondrial-Mediated Apoptosis Through Proteasomal Dysfunction
Upadhyay, A., Amanullah, A., Chhangani, D., Joshi, V., Mishra, R., & Mishra, A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9603-6 · Cited by 30
Self-citationMolecular features that predict the response to antimetabolite chemotherapies
Mehrmohamadi, M., Jeong, S. H., & Locasale, J. W. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0170-3 · Cited by 30
Grob, J., Garbe, C., Ascierto, P. A., Larkin, J., Dummer, R., & Schadendorf, D. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30596-5 · Cited by 30
Omar, A., Kalra, R. S., Putri, J. F., Elwakeel, A., Kaul, S. C., & Wadhwa, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-62953-5 · Cited by 30
CARF (Collaborator of ARF) overexpression in p53‐deficient cells promotes carcinogenesis
Kalra, R. S., Cheung, C., Chaudhary, A., Prakash, J., Kaul, S. C., & Wadhwa, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.07.003 · Cited by 29
Self-citationGuo, Y., Shi, M., Shen, X., Chen, Y., Yang, L., & Zhang, J. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.12.004 · Cited by 29
Bruni, E., Reichle, A., Scimeca, M., Bonanno, E., & Ghibelli, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01307 · Cited by 29
Hulen, T. M., Chamberlain, C. A., Svane, I. M., & Met, Ö. (2021) · Immuno · doi:10.3390/immuno1030012 · Cited by 29
Lara, L. I., Fenner, S., Ratcliffe, S. J., Isidro‐Llobet, A., Hann, M. M., Bax, B. D., & Osheroff, N. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky072 · Cited by 28
Altinoz, M. A., Özpınar, A., Emekli‐Alturfan, E., et al. (2018) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1487149 · Cited by 26
Gambara, G., Gaebler, M., Keilholz, U., Regenbrecht, C. R. A., & Silvestri, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00077 · Cited by 25
Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells
Sannino, S., Guerriero, C. J., Sabnis, A. J., Stolz, D. B., Wallace, C. T., Wipf, P., Watkins, S. C., Bivona, T. G., & Brodsky, J. L. (2018) · Journal of Cell Science · doi:10.1242/jcs.217760 · Cited by 24
Caccuri, F., Sommariva, M., Marsico, S., Giordano, F., Zani, A., Giacomini, A., Fraefel, C., Balsari, A., & Caruso, A. (2019) · Cancers · doi:10.3390/cancers11071006 · Cited by 24
Wang, H., & Wang, Y. (2010) · Analytical Chemistry · doi:10.1021/ac1008628 · Cited by 23
Factors Determining Sensitivity and Resistance of Tumor Cells to Arsenic Trioxide
Sertel, S., Tome, M. E., Briehl, M. M., Bauer, J., Hock, K., Plinkert, P. K., & Efferth, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035584 · Cited by 23
Rodrigues, D., de Souza, T. M., Jennen, D. G. J., Lemmens, L., Kleinjans, J. C. S., & de Kok, T. M. C. M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.004 · Cited by 23
TCR gene-engineered cell therapy for solid tumors
Tan, E. S., Gakhar, N., & Kirtane, K. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101285 · Cited by 23
Chen, X., Ji, S., Si, J., Zhang, X., Wang, X., Guo, Y. X., & Zou, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11629 · Cited by 21
Chaudhary, A., Kalra, R. S., Huang, C., Prakash, J., Kaul, S. C., & Wadhwa, R. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00573 · Cited by 20
Self-citationExpression Proteomics Predicts Loss of RXR-γ during Progression of Epithelial Ovarian Cancer
Kalra, R. S., & Bapat, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070398 · Cited by 19
Porter, R. J., Murray, G. I., Alnabulsi, A., Humphries, M. P., James, J. A., Salto‐Tellez, M., Craig, S. G., Wang, J. M., Yoshimura, T., & McLean, M. H. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.222 · Cited by 19
Yerram, P., Reiss, S., Modelevsky, L. R., Gavrilovic, I. T., & Kaley, T. J. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03266-0 · Cited by 18
Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules
KuKanich, B. K., Warner, M., & Hahn, K. A. (2017) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.250.3.322 · Cited by 16
Rethinking the adenosine-A2AR checkpoint: implications for enhancing anti-tumor immunotherapy
Helms, R. S., & Powell, J. D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.003 · Cited by 14
Pharmacokinetic Study of High Dose Etoposide Infusion in Patients with Small Cell Lung Cancer
Green, J. A., Tarpey, A. W., & Warenius, H. M. (1988) · Acta Oncologica · doi:10.3109/02841868809094365 · Cited by 13
Autophagy Induced by Proteasomal DUB Inhibitor NiPT Restricts NiPT-Mediated Cancer Cell Death
Chen, J., Chen, X., Xu, D., Yang, L., Yang, Z., Yang, Q., Ding, Y., Zhang, P., Feng, D., & Liu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00348 · Cited by 11
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
Jazirehi, A. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111726 · Cited by 9
Carboplatin plus etoposide or topotecan for small-cell lung cancer
Arrieta, O. G., Lara‐Mejía, L., & Zatarain-Barrón, Z. L. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30427-7 · Cited by 6
New advances in the treatment of atrial fibrillation: focus on stroke prevention
Lau, Y. C., & Lip, G. Y. H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.948418 · Cited by 4
Cited by
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Self-citationBridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Histone methyltransferase KMT2A: developmental regulation to oncogenic transformation
Ogino, J., & Dou, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107791 · Cited by 21
Metadata
- Authors
- Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 10
- Issue
- 4
- Pages
- 1367-1401
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W4221040717
- Cited by
- 1,834
- References
- 300
- FWCI
- 95.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.